Eli Lilly and Company

Philip J Burck

Ronald E Zimmerman

Arvind L Thakkar

C David Jones

Richard L Dunn

Gerald Floyd Smith

Charles V Jackson

The present invention provides adducts of human t-PA derivatives, which comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule. The invention also provides methods for preparing the adducts and compositions for the treatment of thromboembolic disorders.

Compounds and methods for treatment of thromboembolic disorders using an

The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I domains of the native tissue plasminogen activator molecule.

Method of treating thromboembolic disorders by administration of

Long chain alkyl and alkenyl sulfonates, sulfates and sulfoalkyl alkanoate salts, administered intravaginally for contraception.

Contraceptive methods

A contraceptive device for intravaginal use comprising a bioinsoluble, biocompatible polyurethane and an acrosin inhibitor.

Contraceptive device

Introduction of a pharmaceutically acceptable non-toxic cation salt of a straight-chain or branched chain alkyl sulfonate having from 11 to 16 carbon atoms into the uterine lumen or vaginal cavity prevents conception. Sodium tetradecyl sulfonate is preferred.

Contraceptive methods and compositions

Introduction of a pharmaceutically acceptable non-toxic cation salt of a sulfoalkyl alkanoate, for example, sodium sulfopropyl dodecanoate, into the uterine lumen or vaginal cavity prevents conception.

Introduction of a compound of the formula:

Introduction of a pharmaceutically acceptable non-toxic cation salt of a sterol sulfate into the uterine lumen or vaginal cavity prevents conception. Potassium or pyridinium .beta.-sitosteryl sulfate is preferred.

Growing community of inventors

Indianapolis, IN, United States of America

Philip J Burck